中文名稱:D609 | 英文名稱:D609 |
CAS:83373-60-8 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
Cas : 83373-60-8 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號 | 型號 |
D609 | 10mM (in 1mL Water) 5mg 10mg 50mg | 83373-60-8 | EY-Y0165533 |
Cas No.83373-60-8
別名 D-609 potassium, D 609, D-609
化學名 potassium O-(octahydro-1H-4,7-methanoinden-5-yl) carbonodithioate
分子式 C11H15KOS2
分子量 266.47
溶解度 ≥ 35.33 mg/mL in DMSO with gentle warming, ≥ 24.5 mg/mL in EtOH with ultrasonic and warming, ≥ 12.7 mg/mL in H2O
儲存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
PC-PLC hydrolyzes (phosphatidylcholine) PC to generate 1, 2-diacylglycerol (DAG) and phosphocholine. D609 is a widely known inhibitor of PC-PLC and also inhibit sphingomyelin synthase (SMS). Due to these actions, it has antiviral and antitumor properties. D609 does not inhibit bacterial phosphatidylinositol (PI)-PLC, bovine pancreatic PLA2 or phospholipase D from cabbage[1b]. In OVCAR3 cells treated with (53 μg/mL) for 24 h, PC-PLC activity was significantly inhibited and cell proliferation was affected. In breast cancer cells, the activity of PC-PLC decreased 3.5 fold after the incubation with D609 (50 μg/ml) within 1h. The human epidermal growth factor receptor 2 (HER2) was also down-regulated [2]. D609 also has anti-inflammatory functions. It blocked the nitric oxide synthase induced by LPS (IC50=20 μg/mL) and IL-1β induced vascular cell adhesion molecule 1 gene expression in human endothelial cells.[3]
D609 can reduce sphingomyelin synthase, thereby it inhibits bFGF-stimulated astrocyte proliferation. Because of the presence of the thiol function, D609 also has antioxidant/glutathione mimetic properties[1b].
References:
1. a) E. Amtmann, Drugs Exp Clin Res 1996, 22, 287-294; b) R. M. Adibhatla, J. F. Hatcher and A. Gusain, Neurochem Res 2012, 37, 671-679.
2. L. Paris, S. Cecchetti, F. Spadaro, L. Abalsamo, L. Lugini, M. E. Pisanu, E. Iorio, P. G. Natali, C. Ramoni and F. Podo, Breast Cancer Res 2010, 12, R27.
3. a) K. Tschaikowsky, M. Meisner, F. Schonhuber and E. Rugheimer, Br J Pharmacol 1994, 113, 664-668; b) R. R. Cobb, K. A. Felts, G. C. Parry and N. Mackman, Mol Pharmacol 1996, 49, 998-1004. >
成立日期 | 2014-06-05 (11年) | 注冊資本 | 100 |
員工人數(shù) | 50-100人 | 年營業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 生化試劑,抗體,細胞培養(yǎng),分子生物學,免疫安全 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP4年
|
上海冠導生物工程有限公司
|
2025-02-04 | |
¥480 |
上海意杰生物科技有限公司
|
2025-01-30 | ||
¥809.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-01-20 | |
¥198 |
VIP3年
|
TargetMol中國(陶術(shù)生物)
|
2024-12-12 | |
¥500 |
上海偉寰生物科技有限公司
|
2020-01-16 | ||
¥550 |
廣州威佳科技有限公司
|
2020-01-13 | ||
詢價 |
VIP4年
|
上海冠導生物工程有限公司
|
2025-02-04 | |
詢價 |
VIP4年
|
上海冠導生物工程有限公司
|
2025-02-04 | |
詢價 |
VIP4年
|
上海冠導生物工程有限公司
|
2025-02-04 | |
詢價 |
VIP4年
|
上海冠導生物工程有限公司
|
2025-02-04 |